Biotech Top Losers: TESARO Inc. (NASDAQ:TSRO), Dyax Corp. (NASDAQ:DYAX), Regulus Therapeutics (NASDAQ:RGLS), Cara Therapeutics (NASDAQ:CARA)

Tesaro Inc. (NASDAQ:TSRO) announced Thursday morning that it has entered into an exclusive, worldwide license agreement and immuno-oncology antibody collaboration with AnaptysBio Inc. TESARO Inc. (NASDAQ:TSRO) stock performance was -5.40% in last session and finished the day at $36.76. Traded volume was 732,104.00 shares in the last session and the average volume of the stock remained 469,070.00 shares. TESARO Inc. (NASDAQ:TSRO) insider ownership is 21.88%.

Dyax Corp. (NASDAQ:DYAX) on Mar. 14 announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $9.25 per share. Dyax Corp. (NASDAQ:DYAX) dropped -9.11% to $9.23 yesterday on volume of 4.75 million shares. The intra-day range of the stock was $8.94 – $9.30. Dyax Corp. (NASDAQ:DYAX) has a market capitalization of 1.10 billion.

Regulus Therapeutics (NASDAQ:RGLS) had its price target increased by Needham & Company to $14.00 in a research report sent to investors on Friday morning, Analyst Ratings News reports. Regulus Therapeutics Inc. (NASDAQ:RGLS)’s stock on March 14, 2014 reported a lower of -5.02% to the closing price of $10.22. Its fifty two weeks range is $5.83 – $12.89. The total market capitalization recorded 427.36 million. The overall volume in the last trading session was 108,812.00 shares. In its share capital, Regulus Therapeutics Inc. (NASDAQ:RGLS) has 41.82 million outstanding shares.

Equities researchers at Needham & Company LLC assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued on Thursday, Analyst Ratings reports. The firm set a “buy” rating on the stock. On Friday, shares of Cara Therapeutics Inc. (NASDAQ:CARA) dropped -6.35% to close the day at $17.26. Company return on investment (ROI) is 11.50%.